SCHEMBL4583323

SCHEMBL4583323

O=C(NC1CCN(c2ncnc3cc(C#Cc4ccccc4)ccc23)CC1)c1cccc(Cl)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 6/20 0.61
P2RX7 Q99572 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MALT1 Q9UDY8 1/20 0.42
SUV39H1 O43463 1/20 0.42
PRMT1 Q99873 1/20 0.42
SMYD3 Q9H7B4 1/20 0.42
CNR1 P21554 3/20 0.42
CNR2 P34972 2/20 0.42
MAP3K5 Q99683 2/20 0.41
MAP3K6 O95382 1/20 0.41
DRD2 P14416 2/20 0.40
DRD4 P21917 2/20 0.40
DRD3 P35462 2/20 0.40
HTR1A P08908 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017305 0.94 PAK1 (0.55) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4557239 0.91 PAK1 (0.54) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4024025 0.90 PAK1 (0.63) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4016348 0.87 MEN1 (0.49) PAK1P2RX7MEN1KMT2AMAP3K5
SCHEMBL4016410 0.87 PAK1 (0.64) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4024568 0.87 PAK1 (0.68) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4019298 0.86 PAK1 (0.54) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4024042 0.86 PAK1 (0.71) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4018498 0.85 PAK1 (0.62) PAK1P2RX7MEN1KMT2AMALT1
SCHEMBL4020785 0.85 PAK1 (0.66) PAK1P2RX7MEN1KMT2AMALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125463-A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators BAYER SCHERING PHARMA AG (DE) 2008-05-29 US claimed
EP-1903038-A1 N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP claimed
US-20080125463-A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators BAYER SCHERING PHARMA AG (DE) 2008-05-29 US disclosed
EP-1903038-A1 N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125463-A1 N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators PTGER2, PTGER1, PTGDR2 PAK1 1977/4885P2RX7 193/4885MEN1 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.